Invex Therapeutics Ltd. (AU:IXC)
ASX:IXC
Top Page
Invex Therapeutics Ltd.
(Sydney:IXC)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.10
▼(-17.50% Downside)
Action:ReiteratedDate:01/21/26
The score is primarily held back by weak financial performance (volatile and sharply lower revenue, ongoing losses, and persistent cash burn), with some support from a debt-free balance sheet and improving loss/cash outflow trends. Technicals are neutral overall, while valuation remains unattractive due to negative earnings and no dividend yield data.
Positive Factors
Debt-free balance sheet
A zero-debt balance sheet materially reduces refinancing and interest-rate risk for a clinical-stage biotech. This financial conservatism gives management flexibility to pursue trials, partnerships, or staged financing over the next several quarters without an immediate debt service burden.
Negative Factors
Steep revenue decline
An ~81% YoY revenue drop reflects weak commercial validation or one-off revenue loss and materially reduces internally available funding. Persistent top-line volatility undermines ability to self-fund development and increases reliance on external capital, impacting strategic autonomy.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt balance sheet materially reduces refinancing and interest-rate risk for a clinical-stage biotech. This financial conservatism gives management flexibility to pursue trials, partnerships, or staged financing over the next several quarters without an immediate debt service burden.
Read all positive factors
Invex Therapeutics Ltd. (IXC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$7.52M
Dividend YieldN/A
Average Volume (3M)49.57K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue GrowthN/A
EPS Growth71.10%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding75,153,850
10 Day Avg. Volume15,093
30 Day Avg. Volume49,574
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.28
Price to Sales (P/S)29.41
P/FCF Ratio-10.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Invex Therapeutics Ltd. Business Overview & Revenue Model
Company Description
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or in...
How the Company Makes Money
null...
Invex Therapeutics Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 229.08K | 1.21M | 459.08K | 182.25K | 0.00 |
| Gross Profit | 229.08K | 1.21M | 459.08K | 182.25K | 0.00 |
| EBITDA | 0.00 | -720.00K | -8.21M | -4.14M | -2.28M |
| Net Income | -476.87K | -1.64M | -7.75M | -3.95M | -2.28M |
Balance Sheet | |||||
| Total Assets | 5.47M | 6.12M | 22.80M | 29.49M | 32.74M |
| Cash, Cash Equivalents and Short-Term Investments | 5.38M | 6.03M | 22.47M | 29.34M | 32.72M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 220.59K | 431.63K | 1.57M | 1.00M | 658.61K |
| Stockholders Equity | 5.25M | 5.69M | 21.23M | 28.48M | 32.08M |
Cash Flow | |||||
| Free Cash Flow | -652.57K | -2.44M | -6.87M | -3.38M | -1.68M |
| Operating Cash Flow | -652.57K | -2.44M | -6.87M | -3.38M | -1.68M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 0.00 | -14.00M | 0.00 | 0.00 | 8.09M |
Invex Therapeutics Ltd. Technical Analysis
Negative
0.12
Price Trends
0.12
Negative
0.12
Negative
0.11
Negative
Market Momentum
>-0.01
Positive
19.99
Positive
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IXC, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.12, and above the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 19.99 is Positive, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IXC.
Invex Therapeutics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$7.52M | -3.15 | -17.07% | ― | ― | 71.10% | |
45 Neutral | AU$4.42M | -0.15 | 2844.96% | ― | ― | 46.28% | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
41 Neutral | AU$76.13M | -2.12 | -30.19% | ― | ― | 63.46% | |
41 Neutral | AU$138.81M | -2.84 | 279.21% | ― | ― | 0.66% | |
40 Underperform | AU$29.73M | -10.60 | -142.30% | ― | 110.44% | 35.90% |
* Healthcare Sector Average
AU:IXC
Invex Therapeutics Ltd.
0.10
0.03
38.89%
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:ADO
AnteoTech Ltd
0.01
>-0.01
-28.57%
AU:1AD
AdAlta Ltd.
―
―
―
AU:CHM
Chimeric Therapeutics Ltd.
―
―
―
AU:RCE
Recce Pharmaceuticals Ltd.
0.48
0.12
32.96%
Invex Therapeutics Ltd. Corporate Events
Invex Therapeutics Announces Resignation of Joint Company Secretary
Mar 23, 2026
Invex Therapeutics has announced the resignation of joint company secretary Ms Carla Healy, effective 23 March 2026, marking a change in its corporate governance team. The company thanked Ms Healy for her contributions and confirmed that Mr Tim Sl...
Invex Reports Promising Exenatide Data in Alzheimer’s ADBrain™ Model
Jan 22, 2026
Invex Therapeutics reported new data from its research collaboration with Tessara Therapeutics, showing that exenatide demonstrated multiple potentially beneficial effects in Tessara’s ADBrain™ model of Alzheimer’s disease. In th...
Invex Therapeutics Sets Date and Details for 2025 Annual General Meeting
Jan 16, 2026
Invex Therapeutics has announced that its 2025 Annual General Meeting will be held in person at Pathways Corporate in Perth on 17 February 2026 at 3:00pm AWST, with the Notice of Meeting and Explanatory Memorandum made available online via the com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.